SLC5A2 and type 2 diabetes mellitus: In the present study, we retrospectively analyzed consecutive patients with T2D and prescribed SGLT2i in 16 public hospitals in Hong Kong and stratified patients based on known ASCVD or additional CV risk factors (including hypertension and dyslipidemia) aiming to evaluate the impact of early initiation of SGLT2 inhibitor on CV outcomes.